@joryfleischauer

joryfleischauer has been a member of Linktree for 3 years and joined in May 2023. The social media accounts linked to from joryfleischauer are: LinkedIn. Besides social media accounts, joryfleischauer has populated their site with Selling the Script: The Introduction of Private Equity in Retail Pharmacy, Movement Disorder Side Effects Related to Adjunctive Use of an Atypical Antipsychotic in Patients With Major Depressive Disorder, Updates in CLL Treatment: 5-Year Off-Treatment Analyses From the CLL14 and MURANO Trials, Recognizing Negative Symptoms of Schizophrenia, First vs Second-Generation Antipsychotics: How Do They Work?, Mechanisms of Gastrointestinal Inflammation in Crohn’s Disease and Ulcerative Colitis, Changing Payer Management Dynamics at Play in Oncology, What Does Member Disruption Mean to Payers?, Predictors of Treatment-Emergent Affective Switch Video | NP Psych Navigator, Differentiating Unipolar and Bipolar Depression, Understanding Affective Switch in Bipolar I Disorder | NP Psych Navigator, TNF Inhibitors for Treating IBD: How They Work, Crohn’s Disease and Ulcerative Colitis: How Are They Different?, To Crush or Not to Crush: That is the Medication Administration Question, Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study, A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People With Overactive Bladder, Improvement in Motor Consistency and Stability with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: Post Hoc Analysis of Two Phase 3 Clinical Trials | Neurology and Therapy | Springer Nature Link, Risk of malignancy excluding nonmelanoma skin cancer in patients with moderate-to-severe atopic dermatitis in the United States: a population-based study using claims data, Complicated Overactive Bladder Management: Ingenta Connect, Poster & Abstract (ICS 2023) - Real-World Adherence and Persistence of Vibegron Versus Mirabegron and Anticholinergics in Patients With Overactive Bladder: A Retrospective Claims Analysis, Poster (RAV 2024) - Risk of Malignancy Excluding Nonmelanoma Skin Cancer in Patients With Moderate‑to‑Severe Atopic Dermatitis in the United States: A Population-Based Study Using Claims Data, Comparative analysis of real‐world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study, Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis - Advances in Therapy, Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments, Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder, CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis - Drugs - Real World Outcomes, Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder - Drugs - Real World Outcomes.